Natco Pharma - Undervalued or a one product company?

Company on back of Revilimid sales has been posting beyond expectation numbers now and every quarter there is a conesensus the sales would top. But the product seems to have takers in export markets. On back of it and the guidance given by management in Q4FY24 call, this stock is as cheap as it comes.
Moving away from narrative stocks , this is actually a cheap Cash flow stock in every means.
.
On charts front, The stock though lacks some volume, it is on verge of breaking out , Something to add , sit and watch.